Aurinia Pharmaceuticals Inc. (AUPH) Given Consensus Recommendation of “Strong Buy” by Brokerages
Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus target price of $8.67 for the company and are expecting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also given Aurinia Pharmaceuticals an industry rank of 113 out of 265 based on the ratings given to its competitors.
A number of analysts have recently issued reports on the stock. HC Wainwright assumed coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, June 30th. They issued a “buy” rating and a $7.00 price objective on the stock. Canaccord Genuity set a $10.00 price objective on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a report on Friday, August 5th. FBR & Co reiterated an “outperform” rating and issued a $9.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 12th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $7.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/aurinia-pharmaceuticals-inc-auph-given-consensus-recommendation-of-strong-buy-by-brokerages.html
Several institutional investors have recently added to or reduced their stakes in the stock. Abingworth LLP boosted its position in Aurinia Pharmaceuticals by 479.8% in the second quarter. Abingworth LLP now owns 512,036 shares of the company’s stock valued at $1,388,000 after buying an additional 423,729 shares in the last quarter. Lombard Odier Asset Management USA Corp boosted its position in Aurinia Pharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the company’s stock valued at $283,000 after buying an additional 2,813 shares in the last quarter. Finally, Creative Planning purchased a new position in Aurinia Pharmaceuticals during the third quarter valued at $181,000. 20.04% of the stock is owned by institutional investors and hedge funds.
Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down 4.33% during trading on Monday, reaching $3.98. 1,889,736 shares of the company traded hands. Aurinia Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $5.69. The company’s 50-day moving average is $2.77 and its 200 day moving average is $2.83. The company’s market cap is $140.44 million.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.